Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis
Digestive Diseases · 18.08.2026 · 1-24
DOI: 10.1159/000553479 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Digestive Diseases, online erschienen am 18.08.2026. Verfasst von Omar Khasawneh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Family Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
This study aimed to investigate the effects of GLP-1 receptor agonists (GLP-1 RAs) on weight, metabolic, and inflammatory bowel disease (IBD) activity parameters in patients with IBD.
Methods
We conducted a systematic search for studies using GLP-1 RAs in IBD patients. The primary outcomes included weight (body mass index, total body weight, total weight loss percentage [TWL%], and >5 and >10 weight loss [WL]) and metabolic parameters (lipid panel and glycated hemoglobin [HbA1c]), while IBD-activity parameters and adverse events were secondary outcomes.
Results
Ten studies were included (n = 7,831). Weight parameters showed reductions, with a TWL% of −7.55% (95% confidence interval [CI]: −3.99 to −11.12), with 60% achieving WL >5% (95% CI: 53 to 67) and 40% achieving WL >10% (95% CI: 33 to 47). Metabolic parameters showed improved and stabilized levels, of which LDL decreased from 94.96 mg/dL (95% CI: 79.91 to 110.00) to 90.45 mg/dL (95% CI: 81.58 to 99.33), and HbA1c, in diabetics, from 7.11% (95% CI: 6.62 to 7.59) to 6.76% (95% CI: 6.35 to 7.16). GLP-1 RAs seem not to exacerbate IBD activity, with improved fecal calprotectin from 289.46 μg/g (95% CI: 62.88 to 516.04) to 210.59 μg/g (95% CI: 75.45 to 345.73), with 11% and 6% requiring IV steroids and advanced therapy, respectively. Adverse events occurred at lower rates, with nausea/vomiting being the most common.
Conclusion
Our findings suggest that GLP-1 RAs may be promising for reducing weight and improving metabolic parameters without exacerbating activity, and may be a safe option for IBD patients. However, larger randomized controlled trials are needed to assess causal inference and long-term effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health and Family Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
- Faculty of Medicine, Sohag University, Sohag, Egypt.
- Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Azienda-Ospedale Università di Padova, University of Padova, Padova, Italy.
- Faculty of Medicine, Menoufia University, Menoufia, Egypt.
- Faculty of Dentistry, University of Tripoli, Tripoli, Libya.
- Department of Internal Medicine, University of Toledo, Toledo, Ohio, USA.
Zitieren
APA
Khasawneh, O., Gerges, K. M., Khasawneh, I., Savarino, E. V., Barberio, B., Gadelmawla, A. F., Elhabbasi, B. M., Albandak, M., Mohamed, A. T., Shlibek, H. A., Sawaf, B., Regueiro, M., & Elhadi, M. (2026). Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis. Digestive Diseases, 1-24. https://doi.org/10.1159/000553479
Vancouver
Khasawneh O, Gerges KM, Khasawneh I, Savarino EV, Barberio B, Gadelmawla AF, et al. Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis. Digestive Diseases. 2026:1-24. doi:10.1159/000553479
BibTeX
@article{Khasawneh2026,
author = {Khasawneh, Omar and Gerges, Kyrillos Mahrous and Khasawneh, Islam and Savarino, Edoardo V and Barberio, Brigida and Gadelmawla, Ahmed Farid and Elhabbasi, Basma Mansor and Albandak, Maram and Mohamed, Abdelmoneim Taher and Shlibek, Hala Abubkr and Sawaf, Bisher and Regueiro, Miguel and Elhadi, Muhammed},
title = {Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis},
journal = {Digestive Diseases},
year = {2026},
pages = {1--24},
doi = {10.1159/000553479}
}
EUVIMED